The European Technology Platform on Nanomedicine (ETPN) proudly announces its endorsement of the Joint Statement for an Ambitious FP10, published by EARTO and Business Europe. This joint statement, supported by 110 European organizations, advocates for a significant increase in the RD&I budget and emphasizes the importance of pan-European collaborative research as the cornerstone of FP10.
Download and read the document
We invite you to DOWNLOAD, READ & SHARE the full Joint Statement for an Ambitious FP10. Click on the thumbnail below to access the PDF;
Strengthening European Competitiveness
The FP10 Joint Statement highlights the urgent need for the EU to enhance its investments in research, development, and innovation (RD&I) to keep pace with global competitors. The ETPN fully supports this initiative as it aligns with our mission to advance nanotechnology in healthcare and strengthen Europe’s position in the global technology race. Increased funding and collaborative efforts are crucial to fostering innovation, driving technological maturation, and ensuring Europe’s long-term competitiveness.
Promoting Public-Private Partnerships
One of the key aspects of the Joint Statement is the promotion of long-term, trust-based public-private partnerships (PPPs). These partnerships are essential for the uptake of novel technologies and their scale-up into new solutions, products, and services. The ETPN has always been a strong advocate for PPPs, recognizing their vital role in improving people’s well-being and quality of life, and increasing European industrial competitiveness. We actively engage in the Innovative Health Initiative (IHI) public-private partnership with key players such as MedTech Europe, COCIR, and EFPIA.
Synergies with HealthTech
The FP10’s focus on cross-border collaborative RD&I with strong industrial participation is particularly relevant to the health technology sector. By breaking silos and promoting the flow of knowledge between the private and public sectors, as well as between basic and applied research, the FP10 can significantly boost the development and clinical integration of cutting-edge health innovations. The ETPN is excited to leverage these synergies to drive advancements in nanotherapeutics, medical devices, diagnostics, and imaging.
Collaborative Partnerships
Among the 110 signatories of the Joint Statement, we are delighted to see many long-standing partners of ETPN, especially those we have worked closely with during the NOBEL project, which we coordinated to foster synergies in health technologies across Europe (nobel-project.eu). Notable partners include EPOSS, EU Robotics, and Photonics21, that joined the ETPN in the HealthTech4EU Alliance. We are thrilled to continue pushing in the same direction together, aiming for a future where biomedical innovation is a strong point of Europe on the global stage.
About EARTO
The European Association of Research and Technology Organisations (EARTO) represents the interests of over 350 research and technology organisations in Europe. EARTO’s mission is to promote and defend the interests of its members by supporting the development and implementation of R&D and innovation policies in Europe. For more information, visit EARTO.
Our Commitment at the ETPN
The ETPN is committed to supporting this crucial initiative. We believe that by working together with other European associations, we can collectively address complex challenges, accelerate the pace of innovation, and secure Europe’s leadership in key technological domains for breakthrough in healthcare. Our endorsement of the FP10 Joint Statement is a testament to our dedication to fostering a prosperous and sustainable future for European healthcare technologies.
The field of nanomedicine has matured significantly, not only but especially since the COVID-19 crisis, during which its global impact on healthcare could be demonstrations through the nano-encapsulated vaccines, and which accelerated the development of innovative nanomedical applications in clinical settings. Nanomedicine concretely changes already the life of millions of patients worldwide, by improving their diagnosis efficiency therapeutic outcomes (read our article). However, without robust investment, we cannot support the best translational ideas or sustain the technological and fundamental research necessary for future diagnostics, treatments, and nano-enabled vaccines. Nanomedicine needs continued investment to thrive, ensuring today’s innovations reach clinical translation and preparing for the breakthroughs of tomorrow.
We encourage all our members and partners to share this important message and join us in advocating for a competitive and innovative FP10.